Development of the 21-Gene Assay and Its Application in Clinical Practice and Clinical Trials
Top Cited Papers
- 10 February 2008
- journal article
- review article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (5), 721-728
- https://doi.org/10.1200/jco.2007.15.1068
Abstract
Several multigene markers that predict relapse more accurately than classical clinicopathologic features have been developed. The 21-gene assay was developed specifically for patients with estrogen receptor (ER)–positive breast cancer, and has been shown to predict distant recurrence more accurately that classical clinicopathologic features in patients with ER-positive breast cancer and negative axillary nodes treated with adjuvant tamoxifen; validation studies in this population led to its approval as a diagnostic test. In a similar population, it also may be used to assess the benefit of adding chemotherapy to hormonal therapy. Other validation studies indicate that it also predicts the risk of distant and local recurrence in other populations with ER-positive disease, including node-negative patients receiving no adjuvant therapy and patients with positive axillary nodes treated with doxorubicin-containing chemotherapy. The Trial Assigning Individualized Options for Treatment (TAILORx) is multicenter trial that integrates the 21-gene assay into the clinical decision-making process and is designed to refine the utility of the assay in clinical practice and to provide a resource for evaluating additional molecular markers as they are developed in the future.Keywords
This publication has 41 references indexed in Scilit:
- The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer SubtypesClinical Cancer Research, 2007
- The use of gene-expression profiling to better understand the clinical heterogeneity of estrogen receptor positive breast cancers and tamoxifen responseCritical Reviews in Oncology/Hematology, 2007
- Impact of a 21‐gene RT‐PCR assay on treatment decisions in early‐stage breast cancerCancer, 2007
- Concordance among Gene-Expression–Based Predictors for Breast CancerNew England Journal of Medicine, 2006
- Breast Cancer Molecular Subtypes Respond Differently to Preoperative ChemotherapyClinical Cancer Research, 2005
- REporting recommendations for tumour MARKer prognostic studies (REMARK)European Journal Of Cancer, 2005
- A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast CancerNew England Journal of Medicine, 2004
- Gene Expression Signature of Fibroblast Serum Response Predicts Human Cancer Progression: Similarities between Tumors and WoundsPLoS Biology, 2004
- A Gene-Expression Signature as a Predictor of Survival in Breast CancerNew England Journal of Medicine, 2002
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences, 2001